Current status of stentless aortic xenografts
- 1 March 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 15 (2) , 74-81
- https://doi.org/10.1097/00001573-200003000-00002
Abstract
The introduction of the Toronto stentless porcine valve (SPV) (St. Jude, Minneapolis, MN), recently approved by the Food and Drug Administration following a 6-year multi-institutional clinical trial from 1991 to 1997, reflects an evolutionary pursuit of an ideal valve substitute, namely, low thrombogenicity, freedom from anticoagulation, durability, easy availability, resistance to infection, and easy implantability. Currently, four different types of valve replacement have been time tested: mechanical valves, cryopreserved aortic homograft, stented heterograft, and pulmonary autograft (Ross procedure), and none of the available valve substitutes meet all the criteria of an ideal valve. The mechanical valve’s favorable properties of durability and easy implantability are susceptible to thrombus formation, which requires lifelong anticoagulation. Although the aortic homografts are durable, with low incidence of infection and thrombogenicity, their widespread application has been limited by the lack of availability. The pulmonary autograft, with its native aortic valve properties, has been shunned by some surgeons because it requires a demanding technical expertise in implantation and needs an allograft in the pulmonary position. Stented xenografts are characterized by “off-the-shelf” availability, freedom from anticoagulation, easy implantability, and low incidence of infection. Its major drawback has been its limited durability. Another limitation is its residual transvalvular gradient. A modified version, a stentless xenograft, has been introduced to improve hemodynamic profiles in the hope of subsequent superior structural durability and patient survival. Two valves have been approved by the Food and Drug Administration, the Toronto SPV and the Freestyle valve (Medtronic, Minneapolis, MN). At The Methodist Hospital and the Baylor College of Medicine, the Toronto SPV stentless valve has been our stentless xenograft valve of choice. We therefore review the historical evolution, design advantages, surgical techniques, and clinical outcomes of this valve.Keywords
This publication has 20 references indexed in Scilit:
- Twenty-year clinical experience with porcine bioprosthesesThe Annals of Thoracic Surgery, 1996
- Allograft aortic valve replacement: Long-term follow-upThe Annals of Thoracic Surgery, 1995
- Aortic valve replacement: Determinants of operative mortalityThe Annals of Thoracic Surgery, 1994
- Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis: A high risk subgroup identified by preoperative ralation wall thicknessJournal of the American College of Cardiology, 1993
- Valve prosthesis hemodynamics and the problem of high transprosthetic pressure gradientsEuropean Journal of Cardio-Thoracic Surgery, 1992
- The porcine bioprosthetic valveThe Journal of Thoracic and Cardiovascular Surgery, 1985
- Six-year follow-up of glutaraldehyde-preserved heterograftsThe Journal of Thoracic and Cardiovascular Surgery, 1974
- MOUNTED FRESH HOMOGRAFTS FOR AORTIC VALVE REPLACEMENT1The Medical Journal of Australia, 1972
- HOMOGRAFT REPLACEMENT OF THE AORTIC VALVEThe Lancet, 1962
- A METHOD FOR PLACING A TOTAL HOMOLOGOUS AORTIC VALVE IN THE SUBCORONARY POSITIONThe Lancet, 1962